A Prospective, Single-Arm Clinical Trial of Iparomlimab and Tuvonralimab Combined With Spatially Fractionated Radiotherapy and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky Head and Neck Squamous Cell Carcinoma
Latest Information Update: 05 Jul 2025
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary) ; Cisplatin; Docetaxel
- Indications Head and neck cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Jul 2025 New trial record